CXI Healthcare Technology Group

씨엑스아이 · 900120

Financials Diversified Financials · KOSDAQ

Small-cap

Market cap US$10.6M (₩14.6B)

Overview

CXI Healthcare Technology Group makes health supplements, capsules, tablets, granules, and teas, based on traditional Chinese herbal ingredients, and distributes those products primarily in China.

Its subsidiaries also supply raw materials such as cordyceps fungus and tea leaves through their own distribution network, and operate a skincare cosmetics line through major Chinese online platforms. Listed on KOSDAQ, Korea's tech and small-cap board, the company itself is a holding company that does not conduct direct operations, its Chinese subsidiaries and sub-subsidiaries carry out all business activities.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$215.2K

▼ −21.2% YoY

Operating profit · FY2025

US$36.4K

▼ −51.0% YoY

Net income · FY2025

US$47.6K

▼ −58.8% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$273.2K(₩377M)	US$273.1K(₩376.9M)	US$215.2K(₩297M)
Operating profit	US$27.2K(₩37.6M)	US$74.2K(₩102.4M)	US$36.4K(₩50.2M)
Net income	US$28.7K(₩39.6M)	US$115.4K(₩159.3M)	US$47.6K(₩65.7M)

Revenue

FY2023US$273.2K
FY2024US$273.1K
FY2025US$215.2K

Operating profit

FY2023US$27.2K
FY2024US$74.2K
FY2025US$36.4K

Net income

FY2023US$28.7K
FY2024US$115.4K
FY2025US$47.6K

Key ratios (FY2025)

ROE

2.5%

Debt/Eq

0.5%

Op. margin

16.9%

Net margin

22.1%

Rev. YoY

▼ −21.2%

Why it matters

The holding company is incorporated in the Cayman Islands and controls its operating businesses through Chinese subsidiaries, a structure common among overseas-listed groups.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?